AstraZeneca PLC (AZN)

6,280.000
+140.000(+2.28%)
  • Volume:
    70
  • Bid/Ask:
    6,270.000/6,280.000
  • Day's Range:
    6,060.000 - 6,300.000

AZN Overview

Prev. Close
6,140
Day's Range
6,060-6,300
Revenue
3.41T
Open
6,300
52 wk Range
3,401.5-6,995
EPS
-
Volume
70
Market Cap
19.02T
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
456
P/E Ratio
-
Beta
-
1-Year Change
61.98%
Shares Outstanding
1,549,400,665
Next Earnings Date
-
What is your sentiment on AstraZeneca PLC?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC Company Profile

Employees
76100

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company’s marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; Proteros biostructures GmbH to discover and develop novel small molecules. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; and Scorpion Therapeutics, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. The company was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsBuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
  • good
    0
    • hi
      0
      • am new here
        0
        • Anz is a good CIA to buy stock
          0
          • AZN is a good CIA to buy stocks from.
            0
            • how can i invest in this company?
              0
              • hi iam new man.
                0
              • where to buy share
                0
              • I will send you referral. မြန်မာ လား
                0
            • Ytd trade app gave AZN in its daily buy list. 8762 as take profit price and 8031 as stop lossGet ytd trade on app store
              0
              • Useless app
                0
            • invest on Etoro or IG trade
              0
              • People asking how to invest.. capital.com .
                0
                • how do I invest?
                  0
                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.